AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
podophyllotoxin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3481 | 518-28-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK,ZAP70 | 45 | |||
| kinase-selectivity-class | ACVR2B,AXL,EPHB4,GRK2,PDK4 | 5 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 13, 1990 | FDA | ACTAVIS LABS UT INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D06BB04 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Antivirals |
| FDA PE | N0000008732 | Decreased Mitosis |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D000972 | Antineoplastic Agents, Phytogenic |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D007641 | Keratolytic Agents |
| MeSH PA | D050256 | Antimitotic Agents |
| MeSH PA | D050257 | Tubulin Modulators |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50176 | keratolytic drug |
| CHEBI has role | CHEBI:60832 | tubulin modulator |
| CHEBI has role | CHEBI:61951 | microtubule-destabilising agent |
| CHEBI has role | CHEBI:64911 | antimitotic |
| CHEBI has role | CHEBI:76924 | plant metabolite |
Related Drugs by ATC class:
D06BB Antivirals 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Condyloma acuminatum | indication | 240542006 | DOID:11168 |
| Pregnancy, function | contraindication | 289908002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.37 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cytochrome P450 3A4 | Enzyme | IC50 | 6.22 | DRUG MATRIX | |||||
| Glucocorticoid receptor | Nuclear hormone receptor | IC50 | 7.85 | CHEMBL | |||||
| Cytochrome P450 2C9 | Enzyme | IC50 | 5.40 | DRUG MATRIX | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 5.30 | DRUG MATRIX | |||||
| Tubulin | Structural | IC50 | 6 | CHEMBL | |||||
| Regulatory protein E2 | Transcription factor | Kd | 4.70 | CHEMBL | |||||
| Tubulin alpha-1A chain | Structural | IC50 | 6.34 | CHEMBL | |||||
| Regulatory protein E2 | Transcription factor | Kd | 5.98 | CHEMBL | |||||
| Tubulin | Structural | IC50 | 6.34 | CHEMBL | |||||
| Tubulin | Structural | Ki | 5.66 | CHEMBL | |||||
| Human papillomavirus regulatory protein E2 | Transcription factor | Kd | 4.15 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019583 | VUID |
| N0000147681 | NUI |
| D05529 | KEGG_DRUG |
| 4019583 | VANDF |
| C0032334 | UMLSCUI |
| CHEBI:50305 | CHEBI |
| POD | PDB_CHEM_ID |
| CHEMBL61 | ChEMBL_ID |
| D011034 | MESH_DESCRIPTOR_UI |
| DB01179 | DRUGBANK_ID |
| 10607 | PUBCHEM_CID |
| 225782 | RXNORM |
| 5312 | MMSL |
| 003584 | NDDF |
| 415128000 | SNOMEDCT_US |
| 76575003 | SNOMEDCT_US |
| 13598 | IUPHAR_LIGAND_ID |
| L36H50F353 | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Condylox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-6118 | GEL | 5 mg | TOPICAL | NDA | 23 sections |
| PODOFILOX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-0611 | SOLUTION | 5 mg | TOPICAL | ANDA | 23 sections |
| Podofilox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-0621 | GEL | 5 mg | TOPICAL | ANDA | 20 sections |
| Podofilox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6198 | SOLUTION | 5 mg | TOPICAL | NDA authorized generic | 20 sections |